Published in Blood Weekly, June 12th, 2003
"Minimal residual disease (MRD) cells are thought to be responsible for the persistence and relapse of acute myeloid leukemia (AML)," scientists in the Netherlands explained. "Flow cytometric MRD detection by the establishment of a leukemia-associated phenotype (LAP) at diagnosis can be used in 80% of AML patients, allowing detection and functional characterization of MRD in follow-up bone marrow."
"One of the mechanisms contributing to inefficient chemotherapy is apoptosis resistance," noted A. van Stijn and coauthors at the Vrije University of Amsterdam....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.